R2R01
/ River 2 Renal
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
January 31, 2025
Optimization of Single Relaxin B-Chain Peptide Leads to the Identification of R2R01, a Potent, Long-Acting RXFP1 Agonist for Cardiovascular and Renal Diseases.
(PubMed, J Med Chem)
- "Compound 21 (R2R01) was then selected as a candidate for an in-depth characterization. It is currently undergoing phase 2 clinical development for renal and cardiovascular diseases."
Journal • Cardiovascular • Nephrology • Renal Disease
November 29, 2024
R2R01-WHF-201: To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)
(clinicaltrials.gov)
- P2 | N=33 | Completed | Sponsor: River 2 Renal Corp. | Recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Nov 2024
Trial completion • Trial completion date • Cardiovascular • Congestive Heart Failure • Heart Failure
August 26, 2024
R2R01-WHF-201: To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)
(clinicaltrials.gov)
- P2 | N=32 | Recruiting | Sponsor: River 2 Renal Corp. | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure
March 07, 2024
R2R01: A long-acting single-chain peptide agonist of RXFP1 for renal and cardiovascular diseases.
(PubMed, Br J Pharmacol)
- "R2R01 is a potent RXFP1 agonist with an extended half-life that increases renal blood flow in various settings including normotensive and hypertensive conditions. The preclinical efficacy and safety data supported clinical development of R2R01 as a potential new therapy for renal and cardiovascular diseases."
Journal • Allergy • Cardiovascular • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease • CD4
February 16, 2024
R2R01-WHF-201: To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)
(clinicaltrials.gov)
- P2 | N=32 | Not yet recruiting | Sponsor: River 2 Renal Corp.
New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure
1 to 5
Of
5
Go to page
1